Physician profile
Joy Feld
NPI 1982660007
$5,784.59
in general payments reported to CMS, 2019-2025
42 companies · $462 in 2025
The $462 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $908 · 2021: $1,057 · 2022: $1,066 · 2023: $891 · 2024: $646 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,461.58 | 2019-2024 | Trulance, Relistor, Xifaxan |
| Abbvie INC. | $538.13 | 2019-2025 | |
| Amgen INC. | $389.27 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $289.09 | 2021-2025 | |
| Qol Medical, LLC | $242.54 | 2020-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $228.76 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $214.58 | 2019-2025 | Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $210.41 | 2019-2024 | Gattex |
| Merck Sharp & Dohme LLC | $191.93 | 2019-2021 | |
| Gilead Sciences, INC. | $182.77 | 2019-2025 | |
| Daiichi Sankyo INC. | $136.63 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $131.88 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $128.10 | 2020-2024 | Simponi, Simponi Aria, Tremfya |
| Eisai INC. | $106.99 | 2020-2025 | |
| Ardelyx, INC. | $95.63 | 2022-2023 | Ibsrela |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Feld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.